Compare ADMA Biologics Inc (ADMA) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs New York Times Co — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while New York Times Co trades at $73.77 (market cap $11.93B). The key difference: New York Times Co is far larger — about 5.6× ADMA Biologics Inc's market cap, and New York Times Co pays a 1.25% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NYT | |
|---|---|---|
Market Cap | $2.13B | $11.93B |
Sector | Health | Media |
52-Week High | $20.38 | $85.86 |
52-Week Low | $7.60 | $51.43 |
Enterprise Value | $2.20B | $11.33B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
The New York Times Company (NYT) trades at $73.72, showing modest daily movement. The stock exhibits a bullish technical trend with strong moving average signals. Fundamentally, the company demonstrates consistent revenue growth, expanding profit margins, and robust cash flow from operations. Recent quarterly earnings have consistently surpassed analyst expectations, reflecting operational strength. A dividend of $0.23 per share is scheduled for payment in July 2026.
The outlook for NYT is positive, supported by solid financial performance and a 'Buy' analyst consensus with a $78.00 price target, implying potential upside. Key opportunities include sustained digital subscription growth and margin expansion. Primary risks involve competitive pressures in the media landscape and broader economic sensitivity affecting advertising revenue. The stock presents a compelling case for investors seeking a stable, growing media company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
